Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab and Ibrutinib in CLL
NCT02557516Phase 2Terminated
- Sponsor
- Innate Pharma
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab in chronic lymphocytic leukemia (CLL), sponsored by Innate Pharma. Started Nov 2015; status: terminated.
02
Drugs
monalizumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02557516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557516.